阅读说明：本技术 一种供失眠人群食用的含肽组合物及应用 (Peptide-containing composition for insomnia people and application thereof ) 是由 张珍妮 于 2019-11-01 设计创作，主要内容包括：本发明属于保健食品、功能性食品技术领域,具体涉及一种供失眠人群食用的含肽组合物及其应用。本发明所述组合物以牛骨低聚肽粉、酸枣仁粉、黑芝麻粉、龙眼肉粉、核桃低聚肽粉为主要成分,辅以辅料制备成一种供失眠人群食用的含肽组合物,所述组合物具有宁心安神的功效,改善心悸不安、失眠方面的效果显著,可用于制备辅助改善心悸不安、失眠的产品。(The invention belongs to the technical field of health-care food and functional food, and particularly relates to a peptide-containing composition for insomnia people and application thereof. The peptide-containing composition for insomnia people is prepared from the bovine bone oligopeptide powder, the spina date seed powder, the black sesame powder, the longan pulp powder and the walnut oligopeptide powder as main components and auxiliary materials.)

1. A peptide-containing composition for insomnia people is characterized by comprising cow bone oligopeptide powder, spina date seed powder, black sesame powder, longan pulp powder and walnut oligopeptide powder.

2. The peptide-containing composition according to claim 1, wherein the oligopeptide powder from cow bones is 2 to 5 parts, the semen Ziziphi Spinosae powder is 0.5 to 1 part, the semen Sesami nigrum powder is 0.5 to 1 part, the arillus longan powder is 0.5 to 1 part, and the walnut oligopeptide powder is 1 to 3 parts by weight.

3. The peptide-containing composition of claim 1, further comprising an excipient, wherein the excipient is at least one of a flavorant, a sweetener, and a vitamin complex.

4. The peptide-containing composition according to claim 3, wherein the flavor composition comprises, by weight, 0.01 to 0.5 parts of a flavorant, 0.01 to 0.5 parts of a sweetener, and 0.01 to 0.2 parts of a vitamin complex.

5. The peptide-containing composition of claim 1, wherein the bovine bone oligopeptide powder is prepared by the following preparation method:

fresh ox bone is used as a raw material, and the ox bone oligopeptide powder is prepared by the processes of crushing, cleaning, high-pressure extraction, enzymolysis by compound protease, filtering and concentration in sequence, with or without food additives of citric acid and food essence, mixing and drying.

6. The peptide-containing composition of claim 1, wherein the walnut oligopeptide powder is prepared by the following preparation method:

fresh walnuts are used as raw materials, and are subjected to high-pressure extraction, complex enzyme enzymolysis, filtration, concentration and drying to prepare the walnut oligopeptide powder.

7. Use of a peptide-containing composition according to any one of claims 1 to 6 for the preparation of a product for aiding in the amelioration of palpitation and insomnia.

Technical Field

The invention belongs to the technical field of health-care food and functional food, and particularly relates to a peptide-containing composition for insomnia people and application thereof.

Background

Insomnia refers to the failure to fall asleep or to maintain a state of sleep, resulting in insufficient sleep. It is also called as sleep-in and sleep-maintaining disorder, and is a common disease caused by various reasons, such as difficulty in sleep-in, too short sleep depth or frequency, early awakening, insufficient sleep time or poor quality. Insomnia can be classified into primary and secondary types according to its etiology. Primary insomnia usually lacks a definite cause or remains insomnia symptoms after excluding causes that may cause insomnia, mainly including psychophysiological insomnia, idiopathic insomnia and subjective insomnia of 3 types. The diagnosis of primary insomnia lacks specific indexes, and is mainly an exclusionary diagnosis. Primary insomnia is considered to be caused when insomnia symptoms remain after the etiology that may cause insomnia is eliminated or cured. According to the psychological and physiological insomnia, the etiology can be traced to the influence of a certain or long-term event on the functional stability of the peripheral system of the brain of a patient, and the imbalance of the functional stability of the peripheral system finally causes the disorder of the brain sleep function and the insomnia. Secondary insomnia includes insomnia due to physical diseases, mental disorders, drug abuse, etc., and insomnia associated with sleep disordered breathing, sleep movement disorder, etc. Insomnia frequently occurs simultaneously with other diseases, and sometimes it is difficult to determine the causal relationship between these diseases and insomnia, so in recent years the concept of comorbidinsomnia has been proposed to describe those insomnia that are accompanied simultaneously with other diseases.

The clinical manifestations of insomnia patients mainly include the following aspects: 1. disorders in the sleep process, difficulty falling asleep, decreased sleep quality and decreased sleep time; 2. daytime sleepiness is caused by daytime cognitive dysfunction, memory function decline, attention function decline and planning function decline, and working capacity decline is easy to occur when the work is stopped; 3. vegetative nerve functional disturbance of the limbic system of the brain and its surroundings; 4. other systemic symptoms, short-term decreased endosome weight, decreased immune function and endocrine dysfunction are likely to occur. Insomnia often brings great pain and psychological burden to patients, and damages other aspects of the body due to abuse of insomnia drugs.

At present, the main intervention measure for insomnia is drug treatment. Although the variety of drugs with hypnotic effect is wide, most of them are not mainly used for treating insomnia. At present, the drugs for clinically treating insomnia mainly comprise benzodiazepine receptor agonists (BZRAs), melatonin receptor agonists and antidepressant drugs with hypnotic effect. Although antihistamine (such as diphenhydramine), melatonin and valerian extract have hypnotic effect, the existing clinical research evidence is limited, and the extract is not suitable for conventional insomnia medication. General treatment recommendations: eszopiclone, zolpidem, controlled release zolpidem (zolpidem-CR), zopiclone. The drugs for treating insomnia are complex and numerous and include estazolam (estazolam), fluzepam (fluazepam), quazepam (quazepam), temazepam (temazepam), triazolam (triazolam), alprazolam (alprazolam), chlordiazepoxide (chloredizoxazole), diazepam (diazepam), lorazepam (lorazepam), midazolam (midazolam), zolpidem controlled release agent (zolpidem-CR), zopiclone (zopiclone), eszopiclone (eszopiclone), and zaleplon (zaleplon), ramelteon (ramelteon), tesmetilene (tameton in-phase, tasimelteon), agomelatine (agomelatine), trimeprazin, tritone, 5-selective inhibitors (SStryptamine re-uptake inhibitors), re-selective inhibitors (ritzazapine, re-5-related, and the like, and small re-inhibiting doses of norepinephrine. Because some drugs may be dependent on them, they are generally not suitable for long-term administration.

Disclosure of Invention

In view of the above, the present invention aims to provide a peptide-containing composition for insomnia people and its application.

In order to realize the purpose of the invention, the invention adopts the following technical scheme:

a peptide-containing composition for insomnia people comprises Os bovis Seu Bubali oligopeptide powder, semen Ziziphi Spinosae powder, semen Sesami Niger powder, arillus longan powder, and semen Juglandis oligopeptide powder.

Preferably, the feed comprises, by weight, 2-5 parts of beef bone oligopeptide powder, 0.5-1 part of spina date seed powder, 0.5-1 part of black sesame seed powder, 0.5-1 part of longan pulp powder and 1-3 parts of walnut oligopeptide powder.

In some embodiments, the peptide-containing composition further comprises an adjuvant, wherein the adjuvant is at least one of a flavoring essence, a sweetener, and a vitamin complex. That is, the peptide-containing composition may or may not be supplemented with flavorants, sweeteners, or multivitamins.

Preferably, the peptide-containing composition comprises 0.01 to 0.5 parts of edible essence, 0.01 to 0.5 parts of sweetening agent and 0.01 to 0.2 parts of compound vitamin by weight.

In some embodiments, the peptide-containing composition consists of 2 parts by weight of bovine bone oligopeptide powder, 1 part by weight of spina date seed powder, 0.5 part by weight of black sesame seed powder, 1 part by weight of longan pulp powder and 1 part by weight of walnut oligopeptide powder.

In some embodiments, the peptide-containing composition consists of 5 parts by weight of bovine bone oligopeptide powder, 0.5 part by weight of spina date seed powder, 1 part by weight of black sesame seed, 0.5 part by weight of longan pulp powder, 3 parts by weight of walnut oligopeptide powder and 0.2 part by weight of vitamin complex.

In some embodiments, the peptide-containing composition consists of 2 parts by weight of bovine bone oligopeptide powder, 0.5 part by weight of spina date seed powder, 0.5 part by weight of black sesame seed powder, 0.5 part by weight of longan pulp powder, 1 part by weight of walnut oligopeptide powder, 0.5 part by weight of sweetener and 0.01 part by weight of vitamin complex.

In some embodiments, the peptide-containing composition consists of 5 parts by weight of beef bone oligopeptide powder, 1 part by weight of spina date seed powder, 1 part by weight of black sesame seed powder, 1 part by weight of longan pulp powder, 3 parts by weight of walnut oligopeptide powder, 0.01 part by weight of edible essence, 0.01 part by weight of sweetener and 0.2 part by weight of vitamin complex.

The components of the peptide-containing compositions of the present invention are commercially available.

In some embodiments, the bovine bone oligopeptide powder is prepared by the following preparation method: fresh ox bone is used as a raw material, and the ox bone oligopeptide powder is prepared by the processes of crushing, cleaning, high-pressure extraction, enzymolysis by compound protease, filtering and concentration in sequence, with or without food additives of citric acid and food essence, mixing and drying.

In some embodiments, the walnut oligopeptide powder is prepared by the following preparation method:

fresh walnuts are used as raw materials, and are subjected to high-pressure extraction, complex enzyme enzymolysis, filtration, concentration and drying to prepare the walnut oligopeptide powder.

The composition has the effects of calming the heart and soothing the nerves, and has remarkable effects of improving palpitation and insomnia. Therefore, the invention provides the application of the composition in preparing products for assisting in improving palpitation and insomnia.

The peptide-containing composition for insomnia people is prepared from the bovine bone oligopeptide powder, the spina date seed powder, the black sesame powder, the longan pulp powder and the walnut oligopeptide powder as main components and auxiliary materials.

Detailed Description

The invention discloses a peptide-containing composition for insomnia people and application thereof. Those skilled in the art can modify the process parameters appropriately to achieve the desired results with reference to the disclosure herein. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and products of the present invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications of the methods described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of the present invention without departing from the spirit and scope of the invention.

In order to further understand the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Unless otherwise specified, the reagents involved in the examples of the present invention are all commercially available products, and all of them are commercially available.